Core Viewpoint - The company is focusing on high-end generic drugs while accelerating the development of improved new drugs, with a specific emphasis on the antifungal field through its self-developed project XT-0043, which has shown excellent safety and efficacy in Phase II clinical trials and is moving towards Phase III trials [2] Group 1 - The company is deeply engaged in the high-end generic drug market [2] - The first self-developed improved new drug project, XT-0043, is aimed at the antifungal area [2] - XT-0043 has demonstrated outstanding safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [2] Group 2 - The company is currently focusing on advancing the Phase III clinical trial based on the data obtained from Phase II [2]

（文章来源：证券日报） 证券日报网讯 2月11日，恒瑞医药在互动平台回答投资者提问时表示，公司坚持差异化研发策略，以临 床需求为导向，利用领先的技术平台打造差异化创新产品矩阵。例如，公司自主研发的1类创新药瑞拉 芙普α注射液已于2026年1月在国内获批上市，是全球首款获批上市的抗PD-L1/TGF-βRII双特异性抗体 融合蛋白；公司还有100多个自主创新产品正在临床开发，其中不乏具有同类首创/同类最佳潜力的产 品。公司未来还将继续积极探索国际前沿的、具有同类首创或同类最佳潜力的药物靶点，不断产出差异 化、具有创新竞争力的产品。 ...

Core Viewpoint - Yiming Pharmaceutical (002826.SZ) announced a restricted stock incentive plan for 2026, aiming to enhance employee motivation and align their interests with shareholders [1] Group 1: Incentive Plan Details - The incentive plan proposes to grant a total of 3.4038 million restricted shares, which accounts for approximately 1.79% of the company's total share capital of 190.677750 million shares as of the announcement date [1] - A total of 26 individuals will be granted restricted shares under this plan, indicating a targeted approach to incentivizing key personnel [1] - The initial grant price for the restricted shares is set at 10.23 yuan per share, establishing a clear entry point for the incentive [1]

Core Viewpoint - China National Pharmaceutical Modern (600420.SH) announced participation in the national centralized procurement for drugs whose agreements have expired, with 51 drugs from the company and its subsidiaries proposed for selection in the continuation procurement [1] Group 1: Procurement Details - The continuation procurement is organized for drugs from the first to eighth batches of national centralized procurement agreements that have expired [1] - The procurement cycle for the selected drugs will last from the execution of the selection results until December 31, 2028 [1] - The procurement office has not disclosed specific supply prices and quantities for the selected drugs [1] Group 2: Market Impact - Overall, the continuation procurement is expected to maintain price stability, with some drug prices potentially decreasing further [1] - Medical institutions will prioritize the use of the selected drugs during the procurement cycle, ensuring the completion of the agreed procurement volume [1] - The signing of sales contracts for the selected drugs is anticipated to solidify the company's existing market share and enhance its brand influence and market competitiveness [1] - The aforementioned matters are not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The core announcement is that Borui Pharmaceutical's wholly-owned subsidiary, Borui Pharmaceutical (Suzhou) Co., Ltd., has its products selected for the national centralized procurement program, with a procurement period extending until December 31, 2028 [2] - The selected products include Agatroban injection, Micafungin sodium for injection, Oseltamivir phosphate dry suspension, and Oseltamivir phosphate capsules [2] - The total sales of these four products for the first three quarters of 2025 are projected to be 88.8475 million yuan, accounting for 10.16% of the company's revenue [2]

国药现代公告称，公司及下属子公司参加国家集采药品第1 - 8批协议期满品种接续采购，49个药品拟中 选。拟中选药品采购周期至2028年12月31日，2024年度销售收入22.52亿元，占同期营收20.59%；2025 年前三季度销售收入16.02亿元，占同期营收23.15%，无单一品种收入超同期营收5%。本次采购总体价 格稳定，部分或下降，拟中选结果待确认，后续情况存在不确定性。 ...

Core Viewpoint - The company, Anglikang (002940.SZ), has announced its participation in the national organized procurement for the continuation of products whose agreements have expired, with some of its products expected to be selected in the upcoming procurement process [1] Group 1 - The company is involved in the national organized procurement for the first to eighth batches of products whose agreements have expired [1] - The continuation procurement office released the proposed selection results on February 10, 2026, indicating that some of the company's products are likely to be selected [1]

Core Viewpoint - The company announced its participation in the national organized procurement for the continuation of products from the first to eighth batches, aiming to secure contracts for 24 pharmaceutical products, including injectable Cefuroxime Sodium and Clindamycin Phosphate Injection [1] Group 1: Company Participation - The company’s subsidiary, Guangzhou Baiyunshan Tianxin Pharmaceutical Co., Ltd., and its branch, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., are involved in the procurement process [1] - The products targeted for procurement include Cefuroxime Sodium Injection, Clindamycin Phosphate Injection, Mebendazole Tablets, and Amoxicillin Granules among others [1] Group 2: Procurement Details - The procurement is based on the demand reported by medical institutions for each enterprise's products, with the selection price gradient determining the volume ratio [1] - The procurement cycle will last from the actual execution date of the selection results until December 31, 2028 [1]

Core Viewpoint - Heng Rui Medicine's subsidiary, Suzhou Shengdiya Biopharmaceutical Co., Ltd., has received breakthrough therapy designation for its injectable SHR-A1811, marking the 10th indication for this drug [1] Group 1: Product Development - The injectable SHR-A1811 has been approved for domestic market launch in May 2025 [1] - It is indicated for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer who have HER2 activating mutations and have previously received at least one systemic therapy [1]

Core Viewpoint - The company, Anglikang, has announced its participation in the national organized procurement for the continuation of products whose agreements from batches 1-8 have expired, with several products expected to be selected for procurement [1] Group 1: Selected Products - The products proposed for selection include: - Amlodipine Besylate Tablets - Amlodipine Tablets - Aluminum Magnesium Chewable Tablets - Cefalexin Capsules - Cephalexin Capsules - Paliperidone Succinate Tablets - Ticagrelor Tablets - Theophylline Injection - Pregabalin Capsules - Levofloxacin Tablets - Cefuroxime Axetil Capsules - L-Carnitine Injection [1] Group 2: Procurement Details - The continuation procurement is based on the demand reported by medical institutions for each company's products, with the purchasing volume determined according to the selected price gradient [1] - The procurement period will last from the actual execution date of the selection results until December 31, 2028 [1]